Immunotherapy for prostate cancer in sight

Patients with advanced prostate cancer have now been given some hope from a new study. In just a few years' time, Ipilumumab could be approved as a treatment for the world's third-most common type of cancer, researchers predict. Worldwide, prostate cancer is the third-most common form of cancer and is globally the sixth-most common cause of death from cancer among men.